6:10 PM
 | 
May 08, 2013
 |  BC Extra  |  Financial News

Jazz reports 1Q13 results, slides on Xyrem generic competition concerns

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) disclosed in a 10-Q late Tuesday that a modified REMS for narcolepsy drug Xyrem sodium oxybate could include new requirements that could "make it easier for future generic competitors to enter the market and/or negatively affect sales of Xyrem."...

Read the full 202 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >